Both parties will contribute scientifically, with Aptuit providing integrated early discovery capabilities, including medicinal chemistry and pharmacology, as well as drug metabolism and pharmacokinetics, to identify promising compounds for further preclinical development
Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused healthcare group, have entered an agreement under which Aptuit will conduct an integrated discovery project aimed at providing innovative drugs to treat idiopathic pulmonary fibrosis.
Dr Jonathan Goldman, Chief Executive Officer, Aptuit, stated: “This project builds upon the existing relationship between Chiesi and Aptuit in the field of respiratory drug discovery. We are delighted to be working with Chiesi to identify early stage compounds that we hope will ultimately progress into innovative treatments for patients with this debilitating disease.”
Dr Mark Parry Billings, Corporate Drug Development Head, Chiesi Farmaceutici, commented: “We are very pleased to announce the partnership with Aptuit. We share a common culture of scientific excellence and commitment to quality research and development. This alliance will allow our project to progress effectively to the identification of lead compounds with a novel mechanism of action, leveraging our joint expertise in respiratory drug discovery.”